Simplex Trading, LLC Enlivex Therapeutics Ltd. Transaction History

Simplex Trading, LLC

$156 Billion
Q1 2025

A detailed history of Simplex Trading, LLC transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Simplex Trading, LLC holds 1,063 shares of ENLV stock, worth $1,084. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,063

Previous 3,366 68.42%

Holding current value

$1,084

Previous $3,000 66.67%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$0.97 - $1.24 $2,233 - $2,855	-2,303 Reduced 68.42%	1,063 $1,000
Q4 2024 Feb 11, 2025	BUY	$0.84 - $1.69 $2,827 - $5,688	3,366 New	3,366 $3,000
Q1 2024 Apr 25, 2024	BUY	$2.54 - $4.3 $46,382 - $78,522	18,261 New	18,261 $69,000
Q2 2023 Aug 04, 2023	SELL	$2.51 - $3.71 $95 - $140	-38 Reduced 0.3%	12,675 $33,000
Q1 2023 Apr 27, 2023	BUY	$3.41 - $4.55 $15,549 - $20,748	4,560 Added 55.93%	12,713 $46,000
Q4 2022 Feb 02, 2023	BUY	$3.74 - $4.81 $11,320 - $14,559	3,027 Added 59.05%	8,153 $32,000
Q3 2022 Nov 04, 2022	BUY	$4.11 - $5.87 $3,374 - $4,819	821 Added 19.07%	5,126 $21,000
Q2 2022 Aug 03, 2022	BUY	$3.81 - $8.64 $16,402 - $37,195	4,305 New	4,305 $19,000
Q1 2022 May 02, 2022	SELL	$4.92 - $6.66 $50,006 - $67,692	-10,164 Closed	0 $0
Q4 2021 Feb 23, 2022	BUY	$5.81 - $9.73 $59,052 - $98,895	10,164 New	10,164 $63,000
Q2 2021 Aug 12, 2021	SELL	$8.61 - $12.1 $71,333 - $100,248	-8,285 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$9.26 - $24.0 $63,866 - $165,528	6,897 Added 496.9%	8,285 $91,000
Q4 2020 Feb 02, 2021	BUY	$8.16 - $14.5 $11,326 - $20,126	1,388 New	1,388 $11,000

Others Institutions Holding ENLV

# of Institutions

Shares Held

3.18M

Call Options Held

44.3K

Put Options Held

7.1K

View Full List

About Enlivex Therapeutics Ltd.

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $18.8M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

More about ENLV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account

Simplex Trading, LLC Enlivex Therapeutics Ltd. Transaction History